PLEASE REVIEW OUR PRIVACY & COOKIES NOTICE

We use cookies to collect and analyze information on site performance and usage and to ensure you can successfully navigate throughout the site. By clicking the “ACCEPT” button to your right or by clicking on any site content, you agree to the placement of cookies on your computer. For more information, see our Privacy Policy.

 
Locations
 
WEBSITES
  • United States (English)
  • International (English)
  • Chinese (中文)
  • French (Français)
  • German (Deutsch)
  • Italian (Italiano)
  • Japanese (日本語)
  • Russian (Русский)
 

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Investor Relations
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTER
  • Home
  • Products
     
    U.S. ProductsView International Products
    Devices
    Blood Center Devices
    • ACP 215
    • MCS+ 8150
    • MCS+ 9000
    • NexSys PCS
    • PCS 2
    Plasma Center Devices
    • NexSys PCS with Persona Technology
    • NexSys PCS with YES Technology
    • NexSys PCS
    • PCS 2
    Surgical and Diagnostic Devices
    • Cell Saver Elite+
    • Cell Saver 5+
    • Cell Saver Elite
    • TEG
    Software
    Hospital Software
    • BloodTrack
    • SafeTrace Tx
    Plasma Center Software
    • DMS
    • NexLynk DMS
    • NextGen
    Services
    Consulting Services
    • Process Improvement
     
  • Solutions
     
    Blood Management Solutions
    • Solutions for Blood Centers
    • Solutions for Hospitals
    • Solutions for Plasma Centers
     
  • Learning Center
     
    Product Training
    • All Products
    • Blood Centers
    • Hospitals
    • Plasma Centers
    Thought Leadership
    • White Papers & Clinical Reviews
    • Reference Lists
    • Poster Abstracts
    Education
       
    • About Haemonetics
       
      Company Background
      • Overview
      • Historical Timeline
      • Leadership Team
      • Scientific Advisory Council

      • Office Locations
      Investor Relations
      • Investor Relations Home
      • Stock Information
      • Earnings
      • Forecasts & Guidance
      Corporate Responsibility
      • Corporate Responsibility at Haemonetics
      Donors Make It Matter
      • Donors Make It Matter Campaign
      News & Events
      • In the News
      • Calendar of Events
      • Publications
      Careers
      • Careers Overview
      • Open Positions
      • Our Global HQ

      Grants

      • Grant Program

       
    • Customer Support

    Leaving U.S. website

    You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

    YesNo
    • Home
    • About Haemonetics
    • Grants
    • Grant Program
    • Contact Us
    • Print
    • Share

    Haemonetics Investigator Initiated Trial (IIT) Program

    The IIT program at Haemonetics supports original, independent, investigator-initiated research aimed at advancing scientific and clinical knowledge related to hemostasis management. The company reviews unsolicited requests for research support, which may include TEG systems, reagents and/or funding.

    Review Criteria

    Decisions are based upon scientific merit, proposal’s clinical significance, feasibility and likelihood of success given the Principal Investigator’s track record and environment, as well as alignment with Haemonetics’ areas of research interest and availability of resources.

    Submission Process

    Only full protocol submissions will be reviewed by the Scientific Review Committee. However, if you wish to gain insights regarding the company’s interest in your research idea, you can submit a concept form for review by the Medical Director. If you wish to do so, please email the program administrator at HaemoneticsGrantsProgram@Haemonetics.com for a template.

    To submit a protocol for consideration, please email the protocol (see instructions below) along with any supporting documentation to HaemoneticsGrantsProgram@Haemonetics.com.

    • CV or biosketch of the Principal Investigator 
    • Research Plan (in Arial, font size ≥ 11, 1 inch margin on all sides) consisting of: 
      • Introduction – Brief description of problem, hypotheses and aims (1/2 page max) 
      • Approach – Concise overview of the research methods including statistical analysis plan (2 pages max) 
      • Timeline and Budget – Can be in a chart format  (1/2 page max) 
      • References (no page limitation) 

    You will receive an email within 48 hours of your submission to let you know when the next review meeting is scheduled. If you have any questions, please email the program administrator at HaemoneticsGrantsProgram@Haemonetics.com.

    • Contact Us
    • Terms of Use
    • Quality
    • Careers
    • Privacy Policy
    • Site Map

    © 2011-2020 Haemonetics Corporation